About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
SMART QUOTES
Smart
Quotes
Gland Pharma Ltd.
Industry :
Pharmaceuticals & Drugs
BSE Code
543245
ISIN Demat
INE068V01023
Book Value
628.70
NSE Code
GLAND
Dividend Yield %
0.99
Market Cap
300021.45
P/E
25.66
EPS
70.96
Face Value
1
BSE
NSE
20-Feb-2026
BSE
NSE
NSE F & O
20-Feb-2026
BSE
NSE
NSE F & O
Last Price
1821.00
Net Change
-15.25
% Change
-0.83%
Prev.Close
1836.25
Open
1836.30
High
1836.30
Low
1815.25
Volume
609
Last Price
1821.70
Net Change
-18.8
% Change
-1.02%
Prev.Close
1840.50
Open
1825.10
High
1838.10
Low
1813.50
Volume
16540
Value
1109342
Best Buy
0.00
Best Sell
0.00
Best Quantity
0
Sell Quantity
0
Today's Range
1836.30
52-Week High
2130.00
52-Week Low
1200.00
Value
30150836
Best Buy
0.00
Best Sell
1821.70
Best Quantity
0
Sell Quantity
49
Today's Range
1838.10
52-Week High
2131.00
52-Week Low
1277.80
Open Price
High Price
Low Price
Last Price
Prev Close
Change
% Change
Average Price
Underlying Value
Number of contracts traded
Turnover in Rs. Lakhs
Open Interest
Change in O I
% Change in O I
%
Today
|
1W
|
1M
|
1Y
You need to upgrade your Flash Player
Best Bid
Best Offer
Quantity
0
Price
0.00
Quantity
0
Price
0.00
Best Bid
Best Offer
Quantity
0
Price
0.00
Quantity
49
Price
1821.70
Best Bid
Best Offer
Quantity
Price
Quantity
Price
Holding Details
More
Latest Corporate Events
Book Closure
10-Aug-21
26-Aug-21
Dividend
1800 %
14-Aug-25
Company News
18-02-2026
Gland Pharma informs abou...
18-02-2026
Gland Pharma informs abou...
06-02-2026
Gland Pharma gets USFDA’s...
08-01-2026
Gland Pharma rises on get...
07-01-2026
Gland Pharma gets nod for...
04-11-2025
Gland Pharma reports 12% ...
03-11-2025
Gland Pharma informs abou...
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Smart ODR Portal
|
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
|
UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.